FDA Voted Yes on Six Peptides. Now What? The Regulatory Road Ahead

The FDA Pharmacy Compounding Advisory Committee voted to recommend adding six peptides to the 503A Bulks List, a key step in regulating their use in pharmacy compounding; however, the FDA retains final authority and must undergo formal rulemaking before these peptides become lawful for compounding under Section 503A.

This Wire brief sits within Fusion42's coverage of Biotech.